Company intelligence / Profile preview

MedImmune

Gaithersburg*, Maryland*, USAastrazeneca-us.com ↗

Ownership: Private
Employees: ~3000
Development stage: Commercial

Overview

MedImmune developed and commercialized key biologics such as Synagis for RSV prevention and FluMist for influenza. It contributed a robust pipeline spanning infectious disease and oncology. Its technologies were foundational to AstraZeneca’s biologics R&D after the acquisition.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)Vaccines (including live attenuated vaccines)Antibody-drug conjugates[8]
Industry: Biotech

Drug pipeline

79 assets

influenza vaccine live, trivalent

Approved

78 more assets in the full pipeline.

Request access →

Partnerships

Merck & Co.: AIDS/HIV monoclonal antibodies/vaccine development partnership in the early years.[1]NIH/DHHS contracts for pandemic flu vaccine development.[2]

Beyond the preview

Go deeper on MedImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedImmune.

Explore the full profile